✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch | Federal Register PolicySafetyResearch Clinical Summary This regulatory notice documents the Drug...
Schedules of Controlled Substances: Rescheduling of Food and Drug Administration Approved Products Containing Marijuana From Schedule I to Schedule III; Corresponding Change to Permit Requirements
✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch | Federal Register PolicyResearchSafetyIndustry Why This Matters I need the article summary...
Schedules of Controlled Substances: Placement of 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA in Schedule I
✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch | Federal Register PolicySafety Clinical Summary The Drug Enforcement Administration has placed...
Schedules of Controlled Substances: Temporary Placement of Bromazolam in Schedule I
✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch | Federal Register PolicySafetyResearch Why This Matters I need the article summary...
Schedules of Controlled Substances: Placement of 3-Methoxyphencyclidine (1-(1-(3-Methoxyphenyl)cyclohexyl)piperidine) in Schedule I
✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch | Federal Register PolicySafetyResearch Clinical Summary This regulatory action places 3-methoxyphencyclidine (3-MeO-PCP),...
Schedules of Controlled Substances: Placement of MDMB-4en-PINACA in Schedule I
✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch | Federal Register PolicySafetyResearch Why This Matters I don't see a cannabis-related...
Schedules of Controlled Substances: Rescheduling of Food and Drug Administration Approved Products Containing Marijuana From Schedule I to Schedule III; Corresponding Change to Permit Requirements
✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch | Federal Register PolicyResearchSafetyIndustry Why This Matters This rescheduling from Schedule I...
Schedules of Controlled Substances: Placement of 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA in Schedule I
✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch | Federal Register PolicySafety Why This Matters I need the article summary...
Neuroimaging of Adolescent Cannabis Use Treatment
Researchers are investigating whether brain imaging can predict treatment success in adolescent cannabis use disorder treatment programs. This neuroimaging study examines learning-related brain activity in teens before they participate in virtual therapy sessions. The findings could help clinicians personalize cannabis treatment approaches for young patients.
The Use of Cannabidiol Suppositories for Sexual Pain
A new clinical trial is investigating cannabidiol suppositories sexual pain treatment research to address the significant unmet need in sexual health medicine. The study evaluates topical CBD delivery for reducing intimate discomfort over a one-month intervention period. This research could establish evidence for a novel cannabinoid approach to managing sexual pain conditions.